» Articles » PMID: 26759468

Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas

Overview
Journal J Oncol Pract
Specialty Oncology
Date 2016 Jan 14
PMID 26759468
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: BRCA1/2 counseling and mutation testing is recommended for high-risk women, but geographic barriers exist, and no data on the costs and yields of diverse delivery approaches are available.

Methods: We performed an economic evaluation with a randomized clinical trial comparing telephone versus in-person counseling at 14 locations (nine geographically remote). Costs included fixed overhead, variable staff, and patient time costs; research costs were excluded. Outcomes included average per-person costs for pretest counseling; mutations detected; and overall counseling, testing, and disclosure. Sensitivity analyses were performed to assess the impact of uncertainty.

Results: In-person counseling was more costly per person counseled than was telephone counseling ($270 [range, $180 to $400] v $120 [range, $80 to $200], respectively). Counselors averaged 285 miles round-trip to deliver in-person counseling to the participants (three participants per session). There were no differences by arm in mutation detection rates (approximately 10%); therefore, telephone counseling was less costly per positive mutation detected than was in-person counseling ($37,160 [range, $36,080 to$38,920] v $40,330 [range, $38,010 to $43,870]). In-person counseling would only be less costly than telephone counseling if the most favorable assumptions were applied to in personc ounseling and the least favorable assumptions were applied to telephone counseling.

Conclusion: In geographically underserved areas, telephone counseling is less costly than in-person counseling.

Citing Articles

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors.

Yi J, Ballard S, Walsh C, Friedman D, Ganz P, Jacobs L Contemp Clin Trials. 2024; 148():107745.

PMID: 39561920 PMC: 11700757. DOI: 10.1016/j.cct.2024.107745.


Randomized control trial comparing genetic counseling service delivery models in an underserved population.

Lahiri S, Mersch J, Zimmerman J, Mauer Hall C, Moriarty K, Gemmell A J Genet Couns. 2024; 34(2):e1975.

PMID: 39370944 PMC: 11866741. DOI: 10.1002/jgc4.1975.


The growing needs of genetic counselling-Feasibility in utilization of tele-genetic counselling in Asia and Hong Kong.

Chu A, Chung C, Hue S, Chung B Front Genet. 2023; 14:1239817.

PMID: 37600657 PMC: 10435751. DOI: 10.3389/fgene.2023.1239817.


Ethical, legal, and social implications (ELSI) and challenges in the design of a randomized controlled trial to test the online return of cancer genetic research results to U.S. Black women.

Wang C, Bertrand K, Trevino-Talbot M, Flynn M, Ruderman M, Cabral H Contemp Clin Trials. 2023; 132:107309.

PMID: 37516165 PMC: 10544717. DOI: 10.1016/j.cct.2023.107309.


Implementation of a Population-Based Cancer Family History Screening Program for Lynch Syndrome.

Lahiri S, Pirzadeh-Miller S, Moriarty K, Kubiliun N Cancer Control. 2023; 30:10732748231175011.

PMID: 37161761 PMC: 10185972. DOI: 10.1177/10732748231175011.


References
1.
Etter J, Perneger T . Effectiveness of a computer-tailored smoking cessation program: a randomized trial. Arch Intern Med. 2001; 161(21):2596-601. DOI: 10.1001/archinte.161.21.2596. View

2.
Kesselheim A, Cook-Deegan R, Winickoff D, Mello M . Gene patenting--the Supreme Court finally speaks. N Engl J Med. 2013; 369(9):869-75. PMC: 3777541. DOI: 10.1056/NEJMhle1308199. View

3.
Wang G, Beattie M, Ponce N, Phillips K . Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med. 2011; 13(12):1045-50. PMC: 4537294. DOI: 10.1097/GIM.0b013e31822a8113. View

4.
Plevritis S, Kurian A, Sigal B, Daniel B, Ikeda D, Stockdale F . Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006; 295(20):2374-84. DOI: 10.1001/jama.295.20.2374. View

5.
Pataky R, Armstrong L, Chia S, Coldman A, Kim-Sing C, McGillivray B . Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. BMC Cancer. 2013; 13:339. PMC: 3711845. DOI: 10.1186/1471-2407-13-339. View